Activated mouse CD4+Foxp3- T cells facilitate melanoma metastasis via Qa-1-dependent suppression of NK-cell cytotoxicity
The regulatory activities of mouse CD4+Foxp3+ T cells on various immune cells, including NK ceils, have been well documented. Under some conditions, conventional CD4+Foxp3- T cells in the periphery are able to acquire inhibi- tory function on other T cells, but their roles in controlling innate immu...
Saved in:
Published in | Cell research Vol. 22; no. 12; pp. 1696 - 1706 |
---|---|
Main Authors | , , , , , , , , , , , , , , , , , |
Format | Journal Article |
Language | English |
Published |
London
Nature Publishing Group UK
01.12.2012
Nature Publishing Group |
Subjects | |
Online Access | Get full text |
Cover
Loading…
Summary: | The regulatory activities of mouse CD4+Foxp3+ T cells on various immune cells, including NK ceils, have been well documented. Under some conditions, conventional CD4+Foxp3- T cells in the periphery are able to acquire inhibi- tory function on other T cells, but their roles in controlling innate immune cells are poorly defined. As a potential cellular therapy for cancer, ex vivo activated CD4+Foxp3- effector T cells are often infused back in vivo to suppress tumor growth and metastasis. Whether such activated T cells could affect NK-cell control of tumorigenesis is unclear. In the present study, we found that mitogen-activated CD4~Foxp3- T cells exhibited potent suppressor function on NK-cell proliferation and cytotoxicity in vitro, and notably facilitated B16 melanoma metastasis in vivo. Suppression of NK cells by activated CD4+Foxp3- T cells is cell-cell contact dependent and is mediated by Qa-I:NKG2A interac- tion, as administration of antibodies blocking either Qa-1 or NKG2A could completely reverse this suppression, and significantly inhibited otherwise facilitated melanoma metastasis. Moreover, activated CD4+Foxp3- cells from Qa-1 knockout mice completely lost the suppressor activity on NK cells, and failed to facilitate melanoma metastasis when transferred in vivo. Taken together, our findings indicate that innate anti-tumor response is counter regulated by the activation of adaptive immunity, a phenomenon we term as "activation-induced inhibition". Thus, the regulatory role of activated CD4+Foxp3- T cells in NK-cell activity must be taken into consideration in the future design of cancer therapies. |
---|---|
Bibliography: | 31-1568/Q NK cells; T cells; suppression; melanoma; metastasis; Qa-1 The regulatory activities of mouse CD4+Foxp3+ T cells on various immune cells, including NK ceils, have been well documented. Under some conditions, conventional CD4+Foxp3- T cells in the periphery are able to acquire inhibi- tory function on other T cells, but their roles in controlling innate immune cells are poorly defined. As a potential cellular therapy for cancer, ex vivo activated CD4+Foxp3- effector T cells are often infused back in vivo to suppress tumor growth and metastasis. Whether such activated T cells could affect NK-cell control of tumorigenesis is unclear. In the present study, we found that mitogen-activated CD4~Foxp3- T cells exhibited potent suppressor function on NK-cell proliferation and cytotoxicity in vitro, and notably facilitated B16 melanoma metastasis in vivo. Suppression of NK cells by activated CD4+Foxp3- T cells is cell-cell contact dependent and is mediated by Qa-I:NKG2A interac- tion, as administration of antibodies blocking either Qa-1 or NKG2A could completely reverse this suppression, and significantly inhibited otherwise facilitated melanoma metastasis. Moreover, activated CD4+Foxp3- cells from Qa-1 knockout mice completely lost the suppressor activity on NK cells, and failed to facilitate melanoma metastasis when transferred in vivo. Taken together, our findings indicate that innate anti-tumor response is counter regulated by the activation of adaptive immunity, a phenomenon we term as "activation-induced inhibition". Thus, the regulatory role of activated CD4+Foxp3- T cells in NK-cell activity must be taken into consideration in the future design of cancer therapies. ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 These four authors contributed equally to this work. |
ISSN: | 1001-0602 1748-7838 |
DOI: | 10.1038/cr.2012.128 |